Amino Acid Chelated Iron Versus Ferrous Fumarate in the Treatment of Iron Deficiency Anemia With Pregnancy: Randomized Controlled Trial
Iron Deficiency Anemia
About this trial
This is an interventional treatment trial for Iron Deficiency Anemia
Eligibility Criteria
Inclusion Criteria:
- Pregnant women at 14 -18 weeks of gestation calculated from the first day of their last menstrual period and confirmed or modified by ultrasound
- Hemoglobin level 8-10.5 g/dL
- Serum ferritin<15µg/L
Exclusion Criteria:
- The presence of anemia from causes other than iron deficiency(e.g: Folat deficiency anemia,Vitamin B12 deficiency, ect…).
- Multiple gestations
- The presence of clinical and/or laboratory evidence of hepatic, renal, hematological or cardiovascular disease
- Patients with known gastritis
- History of mal-absorption syndrome
- Those with known hypersensitivity to iron preparations
- Those under current iron supplementation
Sites / Locations
- Ain shams university maternity hospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Amino Acid chelated iron tab 15 mg group
Ferrous Fumarate tab 350 mg( 115 mg elemental iron) group
Contain 75 pregnant women will recommended to take ferrotrone(iron chelated amino acid containing 15mg elemental iron) prepared by egyptian pharmaceutical company (nerhadou) once daily (a dose recommended by the company of the product).
Contain 75 pregnant women will recommended to take ferrous fumarate e.g. Hema-caps (ferrous fumarate 350 mg with elemental iron 115mg) prepared by another egyptian pharmaceutical company (Amoun pharmaceutical company) once daily but in sever cases of iron deficiency anemia (Hb<9g/dl) this dose can be doubled as recommended by the company of the product.